Mark R Green. Show Affiliations »
Abstract
Mesh: See more » Adenocarcinoma/drug therapyAdenocarcinoma/geneticsAdenocarcinoma, Bronchiolo-Alveolar/drug therapyAdenocarcinoma, Bronchiolo-Alveolar/geneticsAntineoplastic Agents/therapeutic useCarcinoma, Non-Small-Cell Lung/drug therapyCarcinoma, Non-Small-Cell Lung/geneticsErbB Receptors/geneticsErbB Receptors/metabolismGefitinibGenes, erbB-1HeterozygoteHumansLung Neoplasms/drug therapyLung Neoplasms/geneticsMutationProtein-Tyrosine Kinases/antagonists & inhibitorsQuinazolines/therapeutic useSignal Transduction
Substances: See more » Antineoplastic AgentsQuinazolinesErbB ReceptorsProtein-Tyrosine KinasesGefitinib
Year: 2004 PMID: 15118072 DOI: 10.1056/NEJMe048101
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245